ABSTRACT
BACKGROUND: Oral alendronate, risedronate, and raloxifene are effective treatment options in the management of postmenopausal osteoporosis. There is little previously reported about the renal safety profiles of these three agents in osteoporosis. We aimed to assess the risk of renal toxicity associated with oral alendronate, risedronate, and raloxifene in the treatment of osteoporosis, prospectively. METHODS: One hundred and twenty-seven patients with osteoporosis and osteopenia according to lumbar or femoral-neck bone mineral density t score were enrolled in the study. The patients were randomized to alendronate 70 mg once weekly (n = 47), risedronate 35 mg once weekly (n = 44), or raloxifene 60 mg per day (n = 36) for one year. Preliminary screening included medical history, physical examination, lumbar and femoral bone mineral densitometry measurement, and blood biochemical tests, including renal function tests. The biochemical markers were then assessed at the end of 12 months. RESULTS: There was no significant difference between basal and final renal function parameters of each group. Also these parameters did not differ between the three groups after 12 months of treatment period. CONCLUSIONS: These results demonstrate that alendronate, risedronate, and raloxifene are all safe drugs for renal functions in the treatment of osteoporosis.
Subject(s)
Alendronate/pharmacology , Bone Density Conservation Agents/pharmacology , Etidronic Acid/analogs & derivatives , Kidney/drug effects , Raloxifene Hydrochloride/pharmacology , Aged , C-Reactive Protein/analysis , Calcium/blood , Etidronic Acid/pharmacology , Female , Humans , Kidney Function Tests , Male , Middle Aged , Osteoporosis, Postmenopausal/drug therapy , Osteoporosis, Postmenopausal/physiopathology , Phosphorus/blood , Risedronic Acid , Uric Acid/bloodABSTRACT
Untreated asymptomatic bacteriuria has been associated with acute pyelonephritis, which may have a role in many maternal and fetal complications. Acute pyelonephritis in pregnancy is related to anemia, septicemia, transient renal dysfunction, and pulmonary insufficiency. A randomized study was conducted to assess the clinical and microbiological efficacy of a single dose of fosfomycin trometamol for the treatment of asymptomatic bacteriuria in the second trimester of pregnancy compared with a 5-day regimen of cefuroxime axetyl. Forty-four women received fosfomycin trometamol and 40 women received cefuroxime axetyl. There were no statistically significant differences between both groups regarding the mean age and mean duration of pregnancy. Therapeutic success was achieved in 93.2% of the patients treated with fosfomycin trometamol vs 95% of those treated with cefuroxime axetyl. A single dose of fosfomycin trometamol is a safe and effective alternative in the treatment of asymptomatic urinary tract infections in the second trimester of pregnancy.
Subject(s)
Anti-Bacterial Agents/administration & dosage , Bacteriuria/drug therapy , Fosfomycin/administration & dosage , Pregnancy Complications, Infectious/drug therapy , Pregnancy Trimester, Second , Adult , Age Factors , Cefuroxime/administration & dosage , Cefuroxime/analogs & derivatives , Drug Administration Schedule , Escherichia coli Infections/drug therapy , Female , Humans , Pregnancy , Safety , Single-Blind Method , Treatment OutcomeABSTRACT
Antiphospholipid syndrome (APS) is an autoimmune disorder associated with either arterial and/or venous thrombosis (1). Two cases of APS, which were diagnosed in the second trimester during the diagnostic workup of fetal bradycardia, are presented.
Subject(s)
Antiphospholipid Syndrome/complications , Antiphospholipid Syndrome/diagnosis , Bradycardia/complications , Bradycardia/diagnosis , Fetal Diseases/diagnosis , Adult , Female , Humans , Pregnancy , Pregnancy Trimester, SecondABSTRACT
Myxedematous coma in pregnancy is a rare incident. We present a case of Myxedematous coma in a laboring woman that suggested a pre-eclamptic coma and finalized with a healthy baby.
Subject(s)
Coma/etiology , Myxedema/diagnosis , Obstetric Labor Complications/diagnosis , Pre-Eclampsia/diagnosis , Prenatal Diagnosis , Adult , Diagnosis, Differential , Female , Gravidity , Humans , Infant, Newborn , Myxedema/complications , Pre-Eclampsia/complications , PregnancyABSTRACT
Acardiac twins are usually diagnosed during the antenatal period and almost invariably cause complications to the other fetus. In this case, an acardiac twin pregnancy was misdiagnosed antenatally as a degenerated myoma but ended with delivery of a healthy baby.
